| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 05/08/2002 | CN1348447A 4,5-diaryl-3(i(2H))-furanone derivatives as cyclooxygenase-2 inhibitors |
| 05/08/2002 | CN1348372A 药物用途 Drug use |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/08/2002 | CN1348363A Novel pharmaceutical salt form |
| 05/08/2002 | CN1347729A Rheumatism treating ointment for curing artbralgia |
| 05/08/2002 | CN1347728A Chinese medicine prepn for treating rheumatic osteoarthropathy |
| 05/08/2002 | CN1347711A Antirheumatic medicine and its preparing method |
| 05/08/2002 | CN1347694A Medicine prepn containing matrine or epimatrine and its application in analgesic medicines |
| 05/07/2002 | US6384261 Treating endothelin-mediated disorders; inhibitory binding of endothilin peptides to eta and/or etb receptors; elucidating the physiological and pathophysiological roles and isolating endothelin receptors; antagonists |
| 05/07/2002 | US6384236 N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| 05/07/2002 | US6384225 Intermediates in the preparation of substituted chroman derivatives |
| 05/07/2002 | US6384222 N-benzenesulfonyl-L-proline compounds, preparation method and method for using the compounds in therapy |
| 05/07/2002 | US6384202 Cell-specific active compounds regulated by the cell cycle |
| 05/07/2002 | US6384077 Highly purified EPA for treatment of schizophrenia and related disorders |
| 05/07/2002 | US6384055 Analgesics |
| 05/07/2002 | US6384042 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 05/07/2002 | US6384041 Bicyclic sPLA2 inhibitors |
| 05/07/2002 | US6384037 R-hydroxynefazodone |
| 05/07/2002 | US6384032 Inhibitors of IL-12 production |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383484 Antibodies to truncated VEGF-D and thereof |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA2145000C Compounds which are selective antagonists of the human nk3 receptor and their use as medicinal products and diagnostic tools |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034904A1 Novel g protein-coupled receptor protein and dna thereof |
| 05/02/2002 | WO2002034903A2 Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications |
| 05/02/2002 | WO2002034899A2 Tec kinase assay |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | WO2002034761A1 Pyranoside derivatives |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034751A1 Hexahydro-4-oxoazepino[3,2,1-hi]indoles |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034705A2 C-nitroso compounds and use thereof |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034283A2 Vegh inhibitors and their use |
| 05/02/2002 | WO2002034280A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 05/02/2002 | WO2002034260A1 6-methoxy-2-naphthylacetic acid prodrugs |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034236A2 Lipid formulations for target delivery |
| 05/02/2002 | WO2002034221A1 Dental care compositions |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002011737A3 Anti-inflammatory medicament |
| 05/02/2002 | WO2002004416A3 Lactam metalloprotease inhibitors |
| 05/02/2002 | WO2002000609A3 2,6,7-substituted tetralines useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001095877A3 Porous celecoxib matrices and methods of manufacture thereof |
| 05/02/2002 | WO2001094586A3 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 05/02/2002 | WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 05/02/2002 | WO2001083555A3 Pain signaling molecules |
| 05/02/2002 | WO2001081298A3 Cyclic carboxylic acids as integrin antagonists |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001074900A3 Nuclear factor kb inducing factor |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001070733A3 Di-substituted iminoheterocyclic compounds |
| 05/02/2002 | WO2001064749A3 Method for preparing anti-mif antibodies |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001044264A3 Novel stromelysin inhibitors |
| 05/02/2002 | WO2001040253A3 3-methylene steroid derivative for the treatment of autoimmune diseases |
| 05/02/2002 | WO2001035949A3 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001024828A3 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/02/2002 | WO2001023375A3 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2000069841A3 Benzofuranylaminoalcohols |
| 05/02/2002 | US20020052530 Such as 3-(N-1-indanylamino)-indan-1-one 3-(N-1-indanylamino) indan-1-one formed by reacting amino-indane compound with bromo-indanone compound in presence of triethyleneamine |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052512 Diaminopropionic acid derivatives |
| 05/02/2002 | US20020052508 Heterocyclic thioamide derivatives |
| 05/02/2002 | US20020052475 Cytokines for use in the treatment of autoimmune disease, inflammation, arthritis and multiple sclerosis |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052382 R-hydroxynefazodone |
| 05/02/2002 | US20020052381 Method of using diketopiperazines and composition containing them |
| 05/02/2002 | US20020052378 Novel compounds and compositions as protease inhibitors |
| 05/02/2002 | US20020052375 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| 05/02/2002 | US20020052369 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 05/02/2002 | US20020052350 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 05/02/2002 | US20020052349 p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052333 Therapeutic use of cis-element decoys in vivo |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020051822 Enhancing bone formation, inhibiting osteoclastic differentiation or activating osteoblastic differentialation by administering to a human or animal suffering from, or susceptible to bone disease a lanthanum compound |
| 05/02/2002 | US20020051782 Anti-CCR2 antibodies and methods of use therefor |
| 05/02/2002 | US20020051781 CC-chemokine receptor 2 (CCR2) bound by an immunoglobulin or an antigen-binding fragment |
| 05/02/2002 | US20020051771 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |